News Stocks Kwality Pharmaceuticals Completes Phase 1 Bioequivalence Studies for Three Key DrugsKwality Pharmaceuticals Completes Phase 1 Bioequivalence Studies for Three Key Drugs
Kwality Pharmaceuticals Ltd announced successful completion of Phase 1 of its comprehensive bioequivalence program under SEBI Regulation 30. The company completed BE studies for three key drugs - Hydroxycarbamide, Nilotinib, and Liposomal Amphotericin B - as part of a larger program covering over 30 molecules across Oncology, Cardiology, Anti-diabetics, and Anti-hypertensives. Working with four globally accredited CROs, the company has prepared regulatory dossiers ready for submission across regulated, semi-regulated, and ROW markets.
*this image is generated using AI for illustrative purposes only.
Kwality Pharmaceuticals Ltd has announced the successful completion of Phase 1 of its comprehensive bioequivalence program under Regulation 30 of SEBI listing requirements. The pharmaceutical company has achieved this significant regulatory milestone by completing bioequivalence studies for three key therapeutic products.
Comprehensive Bioequivalence Program Overview
Kwality Pharmaceuticals Ltd had initiated an extensive bioequivalence program covering more than 30 molecules across key therapeutic segments. The program spans critical areas including Oncology, Cardiology, Anti-diabetics, and Anti-hypertensives, comprising a balanced mix of both patented and off-patent complex molecules.
| Program Details: | Specifications |
|---|---|
| Total Molecules: | More than 30 |
| Therapeutic Areas: | Oncology, Cardiology, Anti-diabetics, Anti-hypertensives |
| CRO Partners: | Four globally accredited organizations |
| Execution Structure: | Phased manner |
Phase 1 Completion Details
The company has successfully completed bioequivalence studies for three specific drug products in Phase 1 of the program:
| Product: | Therapeutic Application |
|---|---|
| Hydroxycarbamide: | Oncology/Hematology |
| Nilotinib: | Cancer Treatment |
| Liposomal Amphotericin B: | Antifungal Therapy |
These bioequivalence studies are critical regulatory requirements that demonstrate the therapeutic equivalence of generic formulations to their reference products. The successful completion represents substantial progress in the company's product development pipeline.
Strategic Partnership and Execution
To execute this comprehensive initiative, Kwality Pharmaceuticals has partnered with four globally accredited Contract Research Organizations (CROs). The program has been structured in a phased manner to ensure efficient execution and regulatory alignment across multiple markets.
Regulatory Submission Readiness
With Phase 1 studies complete, the company has prepared comprehensive regulatory dossiers for all three products. These dossiers are now ready for submission across regulated, semi-regulated, and Rest of the World (ROW) markets, further strengthening the company's global regulatory footprint and commitment to expanding access to high-quality pharmaceutical products.
The completion positions Kwality Pharmaceuticals to advance these products through the regulatory approval process and seek marketing authorizations across multiple jurisdictions, potentially expanding its market presence in key therapeutic areas including oncology, hematology, and antifungal treatments.
15
